Sanofi Tries To Quash Bristol Rumors; M&A Efforts Center On Biotech, Japan
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis' merger and acquisition efforts will focus on biotech firms and Japanese companies, CEO Gerard Le Fur maintained Feb. 13
You may also be interested in...
AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas
AstraZeneca's focus on improving manufacturing efficiencies, on the heels of similar moves by Merck and Pfizer, may signal that manufacturing is the next target for industry cost-cutting initiatives
Bristol May Be An Acquisition Target Following Entry Of Plavix Generics
The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target
Sanofi-Aventis Puts Growing Pains Aside, Prepares To Re-Enter M&A Fray
Sanofi-Aventis' merger and acquisition strategy going forward will focus on mid-sized companies